6xcc: Difference between revisions

← Older edit

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
-'''Unreleased structure'''
-The entry 6xcc is ON HOLD  until Paper Publication
+==Structure of the C. botulinum neurotoxin serotype A light chain protease in complex with covalent inhibitor 21==
+<StructureSection load='6xcc' size='340' side='right'caption='[[6xcc]], [[Resolution|resolution]] 1.90&Aring;' scene=''>
+== Structural highlights ==
+<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6XCC OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6XCC FirstGlance]. <br>
+</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.9&#8491;</td></tr>
+<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=UZV:N-hydroxy-5-sulfanylpentanamide'>UZV</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6xcc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6xcc OCA], [https://pdbe.org/6xcc PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6xcc RCSB], [https://www.ebi.ac.uk/pdbsum/6xcc PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6xcc ProSAT]</span></td></tr>
+</table>
+<div style="background-color:#fffaf0;">
+== Publication Abstract from PubMed ==
+Botulinum neurotoxins have remarkable persistence ( approximately weeks to months in cells), outlasting the small-molecule inhibitors designed to target them. To address this disconnect, inhibitors bearing two pharmacophores-a zinc binding group and a Cys-reactive warhead-were designed to leverage both affinity and reactivity. A series of first-generation bifunctional inhibitors was achieved through structure-based inhibitor design. Through X-ray crystallography, engagement of both the catalytic Zn(2+) and Cys165 was confirmed. A second-generation series improved on affinity by incorporating known reversible inhibitor pharmacophores; the mechanism was confirmed by exhaustive dialysis, mass spectrometry, and in vitro evaluation against the C165S mutant. Finally, a third-generation inhibitor was shown to have good cellular activity and low toxicity. In addition to our findings, an alternative method of modeling time-dependent inhibition that simplifies assay setup and allows comparison of inhibition models is discussed.
-Authors: Tararina, M.A., Allen, K.N.
+Catch and Anchor Approach To Combat Both Toxicity and Longevity of Botulinum Toxin A.,Lin L, Olson ME, Sugane T, Turner LD, Tararina MA, Nielsen AL, Kurbanov EK, Pellett S, Johnson EA, Cohen SM, Allen KN, Janda KD J Med Chem. 2020 Sep 18. doi: 10.1021/acs.jmedchem.0c01006. PMID:32886509<ref>PMID:32886509</ref>
-Description: Structure of the C. botulinum neurotoxin serotype A light chain protease in complex with covalent inhibitor 21
+From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-[[Category: Unreleased Structures]]
+</div>
-[[Category: Tararina, M.A]]
+<div class="pdbe-citations 6xcc" style="background-color:#fffaf0;"></div>
-[[Category: Allen, K.N]]
+==See Also==
+*[[Botulinum neurotoxin 3D structures|Botulinum neurotoxin 3D structures]]
+== References ==
+<references/>
+__TOC__
+</StructureSection>
+[[Category: Large Structures]]
+[[Category: Allen KN]]
+[[Category: Tararina MA]]